Observe Medical ASA: Second half and full year interim report

27 Feb 2026 11:40 CET

Oslo, February 27, 2026 - Observe Medical ("the Company" or "Observe Medical")
today releases its results for the second half and the full year of 2025.

Highlights

· Revenue growth: UnoMeterT portfolio revenues of NOK 7.5 million in the
second half, representing an increase of 69% from the same period in 2024. For
the full year the Company recorded revenues from the UnoMeterT portfolio of NOK
18.8 million, a growth of NOK 7.3 million / +64%.
· Successful recapitalisation: The Group raised NOK 58.5 million in gross
proceeds, where NOK 50.5 million was settled in cash through private placements
and a fully subscribed subsequent offering.
· Product innovation: Development of the enhanced version of UnoMeterT SafetiT
Plus, the new UnoMeterT SafetiT Max, with a scheduled commercial launch in
March/April 2026.The new UnoMeterT SafetiT Max, includes patented technology
developed for Sippi®
· Portfolio expansion: Further expanding the product portfolio within the
Urological drainage segment. The planned launch includes 3 new products. In
combination it is estimated that the global market value of these products is at
a level of NOK 1.6-1.8 billion.
· Impairment: The Group recorded an impairment loss of intangible assets
related to Biim Ultrasound totaled NOK 37.7 million in H2 and NOK 41.7 million
for the full year. This has no cash effect.

Subsequent events

· Strengthened liquidity position: The Group has successfully signed a loan
agreement with Innovation Norway of NOK 15 million

Observe Medical invites investors, analysts, and other stakeholders to a
presentation with trading update 25 March 2026, at 10:00 CET. There we will,
among other, focus on our order trajectory inbound 2026, together with the
conclusion from our important UnoMeter Safeti Max test that will be finalized by
March 20, 2026.

The presentation will be streamed via webcast at the following link:
https://qcnl.tv/p/OLaQ0Xa8KdjTtD9W3cv0PQ

For further information, please contact:

Jørgen Mann, CEO Observe Medical
Mobile: +45 408 67 558
E-mail: jorgen.mann@observemedical.com

Johan Fagerli, CFO Observe Medical
Mobile: +47 958 12 765
E-mail: johan.fagerli@observemedical.com

About Observe Medical

Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialization of its broad portfolio of medical technology products, mainly
in urine measurement and ultrasound, in combination with targeted M&A and
distribution. Observe Medical is working with a network of leading distributors
to provide outstanding solutions for healthcare professionals globally.

The Company is headquartered in Oslo, Norway.

Further information is available at www.observemedical.com.

More information:
Access the news on Oslo Bors NewsWeb site

667114_Observe_Medical_ASA_Interim_Report_H2_FY_2025.pdf